Piper Sandler upgraded shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) from a neutral rating to an overweight rating in a report published on Tuesday morning, MarketBeat.com reports. Piper Sandler currently has $3.50 price objective on the biotechnology company’s stock, up from their prior price objective of $2.25. A number of other research firms have […]
Piper Sandler upgraded shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) from a neutral rating to an overweight rating in a research note published on Tuesday, Marketbeat Ratings reports. The brokerage currently has $3.50 price target on the biotechnology company’s stock, up from their prior price target of $2.25. Several other equities analysts have also […]
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 8,750,000 shares, an increase of 143.1% from the April 30th total of 3,600,000 shares. Based on an average trading volume of 6,480,000 shares, […]
CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) was upgraded by analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a research note issued to investors on Tuesday, Marketbeat reports. The firm currently has a $3.50 price objective on the biotechnology company’s stock, up from their prior price objective of $2.25. Piper […]
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 8,750,000 shares, an increase of 143.1% from the April 30th total of 3,600,000 shares. Based on an average daily volume of 6,480,000 shares, the short-interest ratio […]